Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK
Authors:
- 1 November 2006
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 24 (S1) , 21-34
Abstract
Introduction:Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant...Keywords
This publication has 41 references indexed in Scilit:
- PDB10 THE COST-EFFECTIVENESS OF PIOGLITAZONE IN COMBINATION WITH METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SCOTLANDValue in Health, 2004
- Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 dataHealth Economics, 2004
- Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare PerspectivePharmacoEconomics, 2004
- Rosiglitazone increases high-density lipoprotein cholesterol levels in patients with type 2 diabetesJACC, 2003
- UKPDS 60Stroke, 2002
- Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2TM studyExperimental and Clinical Endocrinology & Diabetes, 2002
- Antidiabetic Drugs Present and FutureDrugs, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992